More information about the 2021 event will be made available in the coming months.
Mogrify® has developed a proprietary suite of platform that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). Mogrify is applying its proprietary and award-winning platforms to engineer a renewable and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical. Mogrify is commercializing its technology via a combination of internal therapy development, co-development partnerships, and out-licensing of novel cell conversions applicable to non-core markets.